PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16265606-4 2005 Additions to IFN therapy that can modulate the immune response (e.g., thymosin, isatorbine, or injectable histamine) may improve tolerability of treatment. Histamine 106-115 interferon alpha 1 Homo sapiens 13-16 15361542-6 2004 The lymphocyte apoptosis and nonresponsiveness to IFN-alpha were prevented by two inhibitors of reduced nicotinamide adenine dinucleotide phosphate oxidase-dependent formation of ROS in MPs, histamine dihydrochloride and diphenylene ionodonium, as well as by catalase, a scavenger of ROS. Histamine 191-216 interferon alpha 1 Homo sapiens 50-59 15995323-11 2005 IFN-alpha improves many of the clinical symptoms of SMCD including dermatological, hematological, gastrointestinal, and systemic symptoms associated with histamine release. Histamine 154-163 interferon alpha 1 Homo sapiens 0-9 12453861-1 2002 BACKGROUND: Experimental data had suggested a synergistic effect of histamine with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha). Histamine 68-77 interferon alpha 1 Homo sapiens 126-135 12594246-0 2003 Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells. Histamine 14-23 interferon alpha 1 Homo sapiens 33-42 12594246-3 2003 In this study, we show that human plasmacytoid DC, activated by either CpG oligodeoxynucleotides or viral infection, also respond to histamine through H2 receptors, leading to a marked down-regulation of IFN-alpha and TNF-alpha and a moderate switch in their capacity to polarize naive T cells. Histamine 133-142 interferon alpha 1 Homo sapiens 204-213 15274364-1 2004 BACKGROUND: Histamine inhibits phagocyte-derived production of reactive oxygen species and improves the anti-tumour efficiency of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) in vitro and in tumour-bearing animals. Histamine 12-21 interferon alpha 1 Homo sapiens 173-182 9743456-4 1998 Histamine, a biogenic amine, inhibits ROS formation in MO; thereby, histamine synergizes with IL-2 and with IFN-alpha to induce killing of NK-cell-sensitive human tumor cells in vitro. Histamine 0-9 interferon alpha 1 Homo sapiens 108-117 11996477-18 2002 Whether histamine might improve efficacy with higher doses of IL-2 and IFN-alpha requires further investigation. Histamine 8-17 interferon alpha 1 Homo sapiens 71-80 12225329-2 2002 Histamine dihydrochloride (HDC) has been shown to potentiate the IFN-alpha-induced activation of T cells and NK cells by a mechanism that involves the protection of these lymphocytes against oxygen radical-induced functional inhibition and apoptosis. Histamine 0-25 interferon alpha 1 Homo sapiens 65-74 10808371-4 2000 Histamine inhibits ROS formation in MO via H2-receptors; thereby, histamine protects NK cells from MO-mediated inhibition and synergizes with IL-2 and IFN-alpha to induce killing of NK cell-sensitive human tumor cells in vitro. Histamine 0-9 interferon alpha 1 Homo sapiens 151-160 9743456-7 1998 The results of two pilot trials in metastatic melanoma suggest that the addition of histamine to IL-2/IFN-alpha prolongs survival time and induces regression of tumors, such as liver melanoma, which are considered refractory to immunotherapy with IL-2 or IFN-alpha. Histamine 84-93 interferon alpha 1 Homo sapiens 255-264 9238754-4 1997 Histamine prevents the phagocyte-induced, NK cell-inhibiting signal; thus, histamine and IL-2 or histamine and IFN-alpha synergize to induce NK cell-mediated killing of human tumour cells in vitro. Histamine 0-9 interferon alpha 1 Homo sapiens 111-120 8001030-2 1994 Nine of these patients were given histamine (1 mg s.c.) twice daily during treatment with IL-2 and IFN alpha. Histamine 34-43 interferon alpha 1 Homo sapiens 99-108 8982295-3 1996 Histamine, at concentrations exceeding 0.1 microM, abrogated the monocyte-induced inhibition of NK cells; thereby, histamine and IL-2 or histamine and IFN-alpha synergistically induced NK cell-mediated destruction of AML blasts. Histamine 0-9 interferon alpha 1 Homo sapiens 151-160 2419436-9 1986 Our data suggest that exogenous IFN and IL 2 may have therapeutic potential in the treatment of immunological diseases associated with histamine-induced suppressor cell activity. Histamine 135-144 interferon alpha 1 Homo sapiens 32-35 1485831-2 1992 Viruses belong to the strongest and fast acting inducers of interferon (IFN), which, in turn, may enhance histamine release from effector cells. Histamine 106-115 interferon alpha 1 Homo sapiens 60-70 1485831-2 1992 Viruses belong to the strongest and fast acting inducers of interferon (IFN), which, in turn, may enhance histamine release from effector cells. Histamine 106-115 interferon alpha 1 Homo sapiens 72-75 1640122-2 1992 Monocyte-induced suppression of resting and IFN-activated NK cells was abrogated by the biogenic amines histamine [via H2-type receptors (H2R)] and serotonin [via 5-HT1A-type receptors (5-HT1AR)]. Histamine 104-113 interferon alpha 1 Homo sapiens 44-47 2714424-5 1989 The enhancing effect of cimetidine on IFN alpha inhibition of clonal growth was neutralized by histamine and was not seen with histamine H1 receptor antagonist. Histamine 95-104 interferon alpha 1 Homo sapiens 38-47 23465664-7 2013 Histamine also suppressed LPS-induced myeloid dendritic cell TNF-alpha secretion and suppressed CpG-induced plasmacytoid dendritic cell IFN-alpha gene expression. Histamine 0-9 interferon alpha 1 Homo sapiens 136-145